230 completed, 65 recruiting, 45 active not recruiting, 43 terminated. 158 Not applicable, 118 Phase 2, 49 Phase 1, 45 Phase 3, 10 Early Phase 1.
Follow Carcinoma in Situ: new trials by email Literature Review of Carcinoma in Situ trials Research Report on Carcinoma in Situ
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT) Radiation Therapy, Standard of Care Radiation Therapy, No Intervention - Breast Cancer | Phase 3 | Not yet recruiting | NRG Oncology | 5270 | 2027-01-30 | 2026-09-30 |
| A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors Best Practice, Patient Navigation, Referral - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Not applicable | Recruiting | Ohio State University Comprehensive Cancer Center | 330 | 2026-12-09 | 2026-10-23 |
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
| Addressing Financial Hardship in AYA Cancer Survivors Through the Use of the New LIFT UP Intervention Best Practice, Educational Intervention, Informational Intervention - Breast Ductal Carcinoma In Situ, Hematopoietic and Lymphatic System Neoplasm | Not applicable | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 448 | 2026-11-24 | 2026-11-02 |
| Agentic AI App and Home Bioimpedance Monitoring for Endocrine Therapy Adherence and Lymphedema in Breast Cancer Survivors Cohort1: Pinkmate Agentic AI-ePRO Active Management Platform, Cohort1: Pinkmate Basic Medication Reminders and Standard Outpatient Care, Cohort2: InBody BWA ON Home Bioimpedance Monitoring and Behavioral App - Breast Neoplasm Malignant Primary, Lymphedema Arm | Not applicable | Not yet recruiting | Chang-Ik Yoon | 264 | 2026-10-29 | 2026-11-03 |
| Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS) Magtrace - Ductal Carcinoma in Situ | Phase 2 | Suspended | University of Florida | 30 | 2026-10-01 | 2026-09-11 |
| CAN1012 in Pre-Malignant DCIS and LCIS CAN1012 - Ductal Carcinoma in Situ, Lobular Carcinoma in Situ | Phase 1 | Recruiting | Providence Health & Services | 24 | 2026-09-16 | 2026-09-24 |
| Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions 5-Amino Levulinic Acid - Oral Cancer, Oral Cavity Cancer | Phase 2 | Not yet recruiting | University of Massachusetts, Boston | 65 | 2026-09-01 | 2026-03-19 |
| HISMAR: Intraoperative Margin Assessment Using the Histolog® Scanner to Reduce Reoperation in Breast-Conserving Surgery Histolog® Scanner - Breast Cancer, Ductal Carcinoma In Situ | Not applicable | Not yet recruiting | Hôpital du Valais | 228 | 2026-09-01 | 2026-04-14 |
| Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving Surgery Observation, Endocrine Therapy (Optional) - Ductal Carcinoma In Situ, DCIS | Phase 2 | Recruiting | Fudan University | 234 | 2026-09-01 | 2026-08-13 |
| Personalized Prone Immobilization for Accelerated Partial Breast Radiotherapy VENUS SHELL™ immobilization device - Invasive Breast Cancer Early Stages, Ductal Carcinoma In Situ, DCIS | Not applicable | Recruiting | HeroSupport SA | 30 | 2026-07-02 | 2026-09-23 |
| Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery Adjuvant Radiotherapy, tamoxifen - Ductal Carcinoma In Situ, DCIS | Phase 3 | Recruiting | Fudan University | 636 | 2026-07-01 | 2026-08-13 |
| Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer TARA-002, Investigator's Choice of Intravesical Chemotherapy - Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma | Phase 3 | Recruiting | Protara Therapeutics | 284 | 2026-05-29 | 2026-10-06 |
| Areola Preservation in NSM With Nipple Involvement Areola-Preserving Nipple-Sparing Mastectomy with Immediate Nipple Reconstruction - Breast Cancer, Ductal Carcinoma In Situ, DCIS | Not applicable | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2026-05-01 | 2026-04-22 |
| A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial Starch, Potato - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-04-22 | 2026-04-24 |
| Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC Intravesical Gemcitabine and Docetaxel - Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Recruiting | Michael A. O'Donnell | 174 | 2026-04-10 | 2026-04-17 |
| Breast Tumour Size Measurement by Field Cycling Imaging Field-Cycling Imaging research scan, 3T MRI research scan - Breast Cancer, Ductal Carcinoma In Situ | Not yet recruiting | University of Aberdeen | 12 | 2026-04-01 | 2026-03-25 | |
| Multimodal Imaging With FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of Occult Invasive Cancer [68Ga]Ga-FAPI-46 - Carcinoma, Intraductal, Noninfiltrating | Phase 2 | Recruiting | Universität Münster | 30 | 2026-02-20 | 2026-06-03 |
| A Novel Fluorescent Ductal Needle for Localization and Sampling of Micro Lesions in Breast Ducts novel fluorescent localization marker needle, conventional localization marker needle - Mammary Tumor, Nipple Discharge | Not applicable | Active not recruiting | The Fourth Affiliated Hospital of China Medical University | 300 | 2026-01-01 | 2026-10-13 |
| Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | Phase 2 | Recruiting | Lepu Biopharma Co., Ltd. | 16 | 2025-12-04 | 2026-04-23 |
Showing 20 of 467. Sign in to see all of them.
Carcinoma, Intraductal, Noninfiltrating (283) · Breast Neoplasms (269) · Breast Carcinoma In Situ (189) · Carcinoma, Ductal, Breast (26) · Urinary Bladder Neoplasms (26) · Carcinoma, Lobular (23) · Neoplasms (23) · Non-Muscle Invasive Bladder Neoplasms (18) · Uterine Cervical Neoplasms (16) · Adenocarcinoma in Situ (11) · Hot Flashes (11) · Uterine Cervical Dysplasia (11) · Carcinoma, Transitional Cell (10) · Breast Neoplasms, Male (9)
Neoplasms, Glandular and Epithelial (466) · Neoplasms by Histologic Type (465) · Carcinoma (463) · Neoplasms (444) · Neoplasms by Site (379) · Skin Diseases (324) · Skin and Connective Tissue Diseases (324) · Breast Diseases (319) · Adenocarcinoma (304) · Neoplasms, Ductal, Lobular, and Medullary (293) · Breast Carcinoma In Situ (192) · Pathological Conditions, Signs and Symptoms (62) · Urogenital Diseases (61) · Female Urogenital Diseases and Pregnancy Complications (56)
Tamoxifen (31) · Radiotherapy (18) · Anastrozole (13) · Biopsy (13) · Chemotherapy, Adjuvant (12) · Letrozole (12) · Specimen Handling (12) · Early Intervention, Educational (11) · Methods (9) · Neoadjuvant Therapy (9) · Standard of Care (9) · Immunohistochemistry (8) · Practice Guidelines as Topic (8) · Magnetic Resonance Spectroscopy (7) · Mastectomy, Segmental (7)
Mayo Clinic (19) · National Cancer Institute (NCI) (18) · M.D. Anderson Cancer Center (14) · Ohio State University Comprehensive Cancer Center (14) · Alliance for Clinical Trials in Oncology (9) · Dana-Farber Cancer Institute (8) · Wake Forest University Health Sciences (8) · City of Hope Medical Center (7) · Northwestern University (7) · Case Comprehensive Cancer Center (6) · Jonsson Comprehensive Cancer Center (6) · Rutgers, The State University of New Jersey (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · OHSU Knight Cancer Institute (5) · Roswell Park Cancer Institute (5)
United States (323) · Canada (37) · China (19) · France (18) · United Kingdom (17) · Germany (15) · Italy (15) · South Korea (12) · Australia (11) · Puerto Rico (10) · Switzerland (10) · Denmark (7) · Ireland (7) · Netherlands (7) · Belgium (5)
Vered Stearns, MD (5) · Nicole Simone, MD (4) · Laura Esserman, MD, MBA (3) · Andrea De Censi, MD (2) · Anna Wu (2) · Barbara L. Smith, MD, PhD (2) · Benjamin D Smith (2) · Bruce Haffty, MD (2) · David L Kleinberg, MD (2) · Douglas W. Arthur, MD (2) · Eileen Rakovitch, M.D. (2) · Elinor Sawyer, MD (2)
PMID 23984897, PMID 34469056, PMID 14962527, PMID 16382061, PMID 16461781, PMID 16730270, PMID 17200148, PMID 17234359, PMID 17301074, PMID 17392300, PMID 17492927, PMID 17679725, PMID 17912636, PMID 17998546, PMID 18065731, PMID 18083065, PMID 18097749, PMID 18279765, PMID 18313521, PMID 18332471, PMID 18364505, PMID 18596959, PMID 18786783, PMID 18809612, PMID 18979140, PMID 18981464, PMID 19012935, PMID 19031925, PMID 19096768, PMID 19171491, PMID 19224552, PMID 19231103, PMID 19243946, PMID 19474112, PMID 19528136, PMID 19692688, PMID 19728082, PMID 19826126, PMID 19896789, PMID 20144231, PMID 20385495, PMID 20501712, PMID 20508186, PMID 20562526, PMID 20800381, PMID 20846604, PMID 20888137, PMID 21046229, PMID 21321298, PMID 21335417
P30CA016672 (7), P30CA060553 (7), P30CA006973 (5), P30CA012197 (5), P30CA033572 (5), N01CN00034 (4), P30CA015704 (4), P30CA072720 (4), 2023 (3), P30CA014089 (3), P30CA015083 (3), P30CA036727 (3), P30CA043703 (3), P30CA069533 (3), U10CA037429 (3)